Hepatitis Therapeutics

Hepatitis Therapeutics Market Outlook

The global hepatitis therapeutics market was valued at approximately USD 21 billion in 2022 and is projected to reach around USD 30 billion by 2035, registering a compound annual growth rate (CAGR) of about 5.1% during the forecast period. The increasing prevalence of hepatitis infections, coupled with rising awareness regarding preventive measures and treatment options, is expected to drive market growth significantly. Additionally, innovations in drug development, expansion of healthcare infrastructures, and improvements in access to healthcare services in emerging economies are also contributing to this positive trajectory. Furthermore, the growing demand for effective therapies, especially for hepatitis B and hepatitis C, is motivating pharmaceutical companies to invest substantially in research and development activities aimed at introducing novel and efficient treatment alternatives to the market.

Growth Factor of the Market

The growth of the hepatitis therapeutics market is primarily stimulated by the escalating incidence of hepatitis infections worldwide, particularly in low and middle-income countries where health care access is limited. In addition, rising public health campaigns and government initiatives aimed at increasing screening and vaccination rates have contributed significantly to the demand for hepatitis treatments. The advancements in biotechnology and pharmaceuticals have led to the development of highly effective antiviral therapies and improved immunomodulating agents that enhance patient outcomes. Moreover, the surge in targeted therapies and personalized medicine approaches in the treatment of hepatitis is expected to further bolster market growth. The shift towards combination therapies that enhance efficacy while minimizing side effects is also paving the way for a more comprehensive management of hepatitis infections. Lastly, the growing trend of digital health initiatives, including telemedicine and mobile health applications, is enhancing patient engagement and adherence to treatment regimens, driving market expansion.

Key Highlights of the Market

• Significant growth potential due to the rising incidence of hepatitis infections globally.
• Increasing investment in research and development from pharmaceutical companies.
• Emergence of novel therapies and combination treatments enhancing patient care.
• Government initiatives promoting vaccination and treatment accessibility.
• Growing awareness and education regarding hepatitis prevention and management.

By Product Type

Antiviral Drugs :

Antiviral drugs represent a significant segment of the hepatitis therapeutics market and are primarily employed for managing hepatitis B and C infections. These drugs function by inhibiting the replication of the virus, thus reducing the viral load in patients and improving liver function. The introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment, offering high cure rates and fewer side effects compared to conventional therapies. Additionally, the availability of oral formulations enhances patient compliance and access to treatments. With ongoing research targeting new antiviral compounds and combinations, the segment is expected to witness robust growth, driven by the increasing prevalence of chronic hepatitis infections and a rising patient population in need of effective treatments.

Immunomodulators :

Immunomodulators play a crucial role in the hepatitis therapeutics market by enhancing the body’s immune response against viral infections. These agents are particularly relevant in the management of hepatitis B, where they aid in controlling viral replication and reducing liver inflammation. The use of immunomodulators in combination with antiviral therapies is gaining traction as it has shown improved efficacy and therapeutic outcomes for patients. Furthermore, with the growing understanding of the immune system's role in combating hepatitis, the research focus on developing novel immunomodulatory agents is expected to increase, presenting lucrative growth opportunities for this segment.

Vaccines :

Vaccines are pivotal in the prevention of hepatitis infections, particularly hepatitis A and B. The introduction of effective vaccines has substantially reduced the incidence of these diseases in many parts of the world. The hepatitis B vaccine, in particular, has been incorporated into national immunization programs in various countries, ensuring widespread access and adoption. The ongoing research into developing combination vaccines that can protect against multiple hepatitis strains is expected to provide additional impetus to this segment. Moreover, public health initiatives aimed at increasing vaccination coverage and awareness contribute significantly to the growth of the hepatitis vaccine market.

Interferons :

Interferons, a class of proteins produced by the immune system in response to viral infections, are utilized in hepatitis therapeutics to enhance antiviral defense mechanisms. Interferon therapy has been a cornerstone in the management of chronic hepatitis B and C infections, especially before the advent of DAAs. Despite the side effects associated with interferon treatments, their ability to elicit a strong immune response makes them invaluable in certain patient populations. The ongoing development of pegylated interferons, which offer improved pharmacokinetics and reduced dosing frequency, continues to sustain interest in this segment. Moreover, the therapeutic potential of interferons in combination therapies is being increasingly explored, which may present additional avenues for growth.

Others :

The 'Others' category in the hepatitis therapeutics market encompasses various treatment modalities, including adjunct therapies and experimental agents under investigation. This segment is characterized by the continuous emergence of new therapies and innovations designed to enhance the overall management of hepatitis infections. With significant investments in research and development, companies are keenly focused on exploring alternative treatments that may provide additional options for patients who are resistant to standard therapies. The growing acceptance of novel therapeutic approaches, such as gene therapy and cell-based treatments, presents promising growth prospects for this segment in the coming years.

By Application

Hepatitis B :

The hepatitis B application segment represents a substantial portion of the hepatitis therapeutics market, driven by the high prevalence of chronic hepatitis B infections globally. This viral infection poses a significant public health challenge, leading to serious complications such as cirrhosis and liver cancer. The availability of effective antiviral therapies, including nucleos(t)ide analogs and immunomodulators, has significantly improved treatment outcomes for patients with chronic hepatitis B. Additionally, continuous efforts to increase screening and diagnosis rates are expected to propel market growth, as earlier detection allows for timely initiation of therapy. The demand for combination therapies that enhance efficacy and minimize resistance in hepatitis B treatment is also on the rise, providing further momentum to this application segment.

Hepatitis C :

Hepatitis C is a significant concern, particularly due to its potential to cause chronic liver disease. This application segment has witnessed remarkable advancements due to the introduction of DAAs, which have transformed the treatment landscape for hepatitis C. These therapies are known for their high cure rates, shorter treatment durations, and favorable safety profiles, making them highly sought after by patients and healthcare providers alike. The shift towards prioritizing hepatitis C elimination efforts globally, supported by initiatives from organizations like WHO, is anticipated to drive the demand for hepatitis C therapies further. Continuous monitoring for drug resistance and the exploration of new treatment regimens are also critical aspects contributing to the growth of this segment.

Hepatitis A :

The hepatitis A application segment primarily focuses on preventive measures through vaccination. Although hepatitis A is generally a self-limiting viral infection, outbreaks can occur, necessitating effective vaccination campaigns to control transmission. The availability of effective hepatitis A vaccines, coupled with growing awareness about the importance of vaccinations, is expected to drive market growth in this segment. Public health initiatives aimed at promoting vaccination, particularly in endemic regions and among high-risk populations, are crucial for reducing the incidence of hepatitis A infections. The increasing focus on hygiene and sanitation measures also contributes to the demand for hepatitis A vaccinations.

Others :

The 'Others' segment within the application category includes less common types of hepatitis infections, such as hepatitis D and E, and represents a smaller but noteworthy aspect of the market. Although these infections are not as prevalent as hepatitis B and C, they can pose serious health risks, especially in regions with limited healthcare access. Ongoing research is exploring treatment options for these hepatitis variants, and as awareness grows about their impact, there may be a gradual increase in market demand. Additionally, the potential for new therapies and interventions targeting these infections may provide additional growth opportunities in the future.

By Distribution Channel

Hospitals :

The hospital distribution channel plays a significant role in the hepatitis therapeutics market due to the comprehensive care provided within clinical settings. Hospitals are equipped with advanced diagnostic tools and treatment facilities, enabling them to manage complex hepatitis cases effectively. The presence of specialized healthcare professionals, including hepatologists and infectious disease specialists, contributes to better patient outcomes. Furthermore, hospitals often have established protocols for screening, diagnosing, and treating hepatitis infections, ensuring timely and appropriate care. The increasing number of hospital admissions related to liver diseases is expected to enhance the market share of this channel over the forecast period.

Retail Pharmacies :

Retail pharmacies are crucial for the distribution of hepatitis therapeutics, providing patients with convenient access to prescribed medications. This segment benefits from the growing trend of self-medication and the rising number of patients seeking outpatient care for hepatitis management. Retail pharmacies often engage in awareness campaigns and patient education initiatives, promoting adherence to treatment regimens. The expansion of retail pharmacy chains and improvements in supply chain management further enhance the availability of hepatitis drugs. The increasing focus on chronic disease management, coupled with patient preference for convenience, is expected to drive growth in this distribution channel.

Online Pharmacies :

The online pharmacy segment has gained traction in recent years, particularly due to the COVID-19 pandemic, which accelerated the adoption of digital health solutions. Online pharmacies offer patients a convenient alternative for obtaining hepatitis medications, allowing for discreet purchases and home delivery services. The growing trend of telemedicine and digital consultations has further facilitated the use of online pharmacies for hepatitis therapeutics. Patients benefit from the accessibility of a broader range of products, often at competitive prices. The continuous improvement in online pharmacy platforms and regulations ensuring the safety and efficacy of medications sold online will likely bolster the growth of this distribution channel.

Others :

The 'Others' category within the distribution channel segment includes various alternative channels, such as specialty pharmacies and direct-to-consumer models. Specialty pharmacies play a vital role in managing complex therapies and providing specialized support for patients with hepatitis. These pharmacies often work closely with healthcare providers to ensure proper medication management and adherence to treatment protocols. Additionally, direct-to-consumer models, which involve manufacturers selling their products directly to patients, are gaining momentum as they provide patients with greater control over their treatment options. The increasing focus on personalized medicine and individualized patient care is expected to drive growth within this segment.

By Drug Class

Nucleotide Analog Reverse Transcriptase Inhibitors :

Nucleotide analog reverse transcriptase inhibitors (NRTIs) are crucial components of hepatitis B treatment regimens, primarily used to inhibit viral replication. These agents act by disrupting the viral life cycle, effectively reducing the viral load in infected patients. The efficacy of NRTIs, particularly tenofovir and entecavir, has established them as the first-line therapy for chronic hepatitis B management. Their high barrier to resistance and favorable safety profiles make them invaluable in clinical practice. With ongoing research focused on optimizing treatment regimens and exploring combination therapies that include NRTIs, this drug class is expected to see sustained demand and growth in the hepatitis therapeutics market.

Protease Inhibitors :

Protease inhibitors represent a key class of antiviral drugs, particularly in the treatment of hepatitis C. By inhibiting viral protease enzymes, these agents disrupt the viral replication process, leading to reduced viral loads and improved patient outcomes. The introduction of highly effective protease inhibitors, such as boceprevir and telaprevir, has significantly changed the treatment landscape for hepatitis C, often used in combination with other antiviral agents for enhanced efficacy. Continuous advances in drug development and the exploration of new protease inhibitors with improved pharmacokinetics are expected to contribute positively to this segment's growth in the coming years.

Interferons :

Interferons, while historically significant in the treatment of hepatitis infections, continue to play a relevant role in the hepatitis therapeutics market. These agents are particularly effective in the management of chronic hepatitis B and C infections, stimulating the immune system to fight the virus. The development of pegylated interferons has improved their tolerability and reduced the frequency of administration, leading to better patient adherence. Despite the emergence of newer therapies, interferons remain an essential treatment option in specific patient populations, particularly for those who may not respond to direct-acting antivirals. The ongoing research into optimizing interferon therapies and combining them with other antiviral drugs may further enhance their role in hepatitis treatment.

Others :

The 'Others' category within the drug class segment encompasses a range of alternative therapies and experimental agents currently under investigation for hepatitis treatment. This segment is characterized by the dynamic nature of drug development, with ongoing research exploring new mechanisms of action to combat hepatitis infections. Novel therapies targeting specific viral proteins, immune modulation approaches, and gene therapies are being investigated to provide additional options for patients. As the understanding of hepatitis pathophysiology advances and new treatment paradigms emerge, this segment may witness significant growth, driven by the demand for innovative and more effective therapeutics.

By Region

The hepatitis therapeutics market is expected to demonstrate varying growth patterns across different regions, driven by the unique healthcare landscapes, prevalence rates, and treatment access issues. In North America, the market is anticipated to maintain a robust growth trajectory, projected to reach approximately USD 12 billion by 2035, growing at a CAGR of around 5.5%. This growth is propelled by the increasing prevalence of hepatitis infections, along with extensive healthcare infrastructure and significant investment in research and development activities. The North American market is characterized by the presence of numerous pharmaceutical companies and advanced treatment options, contributing to a favorable environment for hepatitis therapeutics.

In Europe, the hepatitis therapeutics market is also expected to witness steady growth, primarily due to the rising awareness of hepatitis treatments and supportive government policies. The European market is expected to reach around USD 9 billion by 2035, with a CAGR of approximately 4.8%. Factors such as the increasing number of screening programs, improved vaccination efforts, and advancements in treatment options are anticipated to drive market growth. Meanwhile, the Asia Pacific region, characterized by a significant burden of hepatitis infections, is expected to showcase substantial growth potential, reaching approximately USD 7 billion by 2035. The growing emphasis on improving healthcare access and affordability, particularly in emerging economies, will be critical to addressing the rising incidence of hepatitis in this region.

Opportunities

The hepatitis therapeutics market presents numerous opportunities driven by the increasing demand for effective and accessible treatment options. A significant opportunity lies in the development of combination therapies that harness the strengths of different drug classes, enhancing overall treatment efficacy while reducing the likelihood of resistance. Continued investments in research and development are essential for discovering novel therapeutic agents and exploring innovative treatment strategies. Furthermore, expanding healthcare access in developing regions is vital in addressing the high prevalence of hepatitis infections, providing a substantial market opportunity for pharmaceutical companies to introduce their products. Collaborative efforts between governments, NGOs, and healthcare providers to promote awareness and education about hepatitis prevention and management can further drive demand for therapeutics, ultimately benefiting the market.

Additionally, the rise of digital health technologies and telemedicine has opened new avenues for the hepatitis therapeutics market, as these solutions enhance patient engagement and adherence to treatment regimens. Digital platforms can facilitate remote consultations, monitoring, and support, improving patient outcomes and reducing barriers to care. Moreover, the implementation of personalized medicine approaches, tailored to individual patient profiles, represents a growing opportunity to enhance treatment effectiveness and patient satisfaction. Companies that invest in innovative therapeutic strategies and digital health initiatives are likely to gain a competitive edge in this evolving market landscape.

Threats

The hepatitis therapeutics market faces several threats that could impede its growth trajectory. One significant challenge is the emergence of drug-resistant viral strains, particularly in hepatitis B and C, which can limit treatment options and necessitate the development of new therapies. The potential for resistance to antiviral therapies underscores the need for ongoing research into innovative treatment regimens and alternative therapeutic approaches. Additionally, the high cost of some advanced therapies, particularly direct-acting antivirals for hepatitis C, may hinder accessibility for certain patient populations, particularly in low-income regions. This disparity in access to effective treatments can contribute to the continued prevalence of hepatitis infections and affect overall market growth.

Moreover, regulatory challenges may pose obstacles to the timely introduction of new therapies into the market. The lengthy and complex drug approval processes can delay access to innovative treatments, limiting the options available to patients. Compounded by the evolving landscape of healthcare policies and reimbursement frameworks, pharmaceutical companies must navigate these challenges effectively to capitalize on market opportunities. The competitive landscape is also becoming increasingly crowded, with numerous players vying for market share, which may lead to price competition that can negatively impact profitability.

Competitor Outlook

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Roche Holding AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Hepatitis B Foundation
• ViiV Healthcare
• Hepion Pharmaceuticals, Inc.
• Echosens
• Intercept Pharmaceuticals, Inc.
• Regulus Therapeutics Inc.
• F. Hoffmann-La Roche AG
• Novartis AG

The competitive landscape of the hepatitis therapeutics market is characterized by the presence of several prominent pharmaceutical companies actively engaged in research, development, and commercialization of innovative therapies. These companies are continuously striving to enhance their product portfolios and address the unmet medical needs associated with hepatitis infections. Gilead Sciences, for instance, is a key player known for its pioneering efforts in developing direct-acting antiviral therapies for hepatitis C, establishing itself as a leader in this segment. In addition to Gilead, AbbVie has made significant strides with its robust offerings in hepatitis C treatments, emphasizing patient-centric approaches and combination therapies.

Merck & Co. is another noteworthy competitor, known for its extensive research initiatives and commitment to advancing hepatology. The company's innovative product pipeline includes promising therapies aimed at improving patient outcomes in hepatitis management. Johnson & Johnson also plays a significant role in the hepatitis therapeutics market, with a focus on developing immunomodulatory agents and vaccines for various hepatitis infections. These companies are leveraging strategic partnerships and collaborations to enhance their research capabilities and expedite the development of new therapies.

In addition to these major players, emerging biotechnology firms such as Hepion Pharmaceuticals and Regulus Therapeutics are making noteworthy contributions to the hepatitis market. These companies focus on developing novel therapeutic agents that address specific aspects of hepatitis treatment, including targeted therapies and investigational drugs. As the market landscape continues to evolve, the competition is expected to intensify, prompting established players to innovate and differentiate their offerings to maintain their market positions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Echosens
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 ViiV Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Holding AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co., Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GlaxoSmithKline plc
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Gilead Sciences, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hepatitis B Foundation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 F. Hoffmann-La Roche AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Regulus Therapeutics Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hepion Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Intercept Pharmaceuticals, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Hepatitis Therapeutics Market, By Drug Class
    • 6.1.1 Nucleotide Analog Reverse Transcriptase Inhibitors
    • 6.1.2 Protease Inhibitors
    • 6.1.3 Interferons
    • 6.1.4 Others
  • 6.2 Hepatitis Therapeutics Market, By Application
    • 6.2.1 Hepatitis B
    • 6.2.2 Hepatitis C
    • 6.2.3 Hepatitis A
    • 6.2.4 Others
  • 6.3 Hepatitis Therapeutics Market, By Product Type
    • 6.3.1 Antiviral Drugs
    • 6.3.2 Immunomodulators
    • 6.3.3 Vaccines
    • 6.3.4 Interferons
    • 6.3.5 Others
  • 6.4 Hepatitis Therapeutics Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Hepatitis Therapeutics Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Hepatitis Therapeutics market is categorized based on

By Product Type

• Antiviral Drugs
• Immunomodulators
• Vaccines
• Interferons
• Others

By Application

• Hepatitis B
• Hepatitis C
• Hepatitis A
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others

By Drug Class

• Nucleotide Analog Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Interferons
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Roche Holding AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Hepatitis B Foundation
• ViiV Healthcare
• Hepion Pharmaceuticals, Inc.
• Echosens
• Intercept Pharmaceuticals, Inc.
• Regulus Therapeutics Inc.
• F. Hoffmann-La Roche AG
• Novartis AG